A limitation of this study was the impossibility of correlating the PD-L1 status evaluated by the combination of IHC scoring on tumour biopsies and of flow cytometry assessment of circulating PD-L1+ MVs with response to immunotherapy, since only standard chemotherapeutic regimens were adopted in our cohort. The gene discussed is CD274; the disease is neoplasm.